Several other research firms have also recently issued reports on OBSV. HC Wainwright set a $27.00 price target on ObsEva SA and gave the company a buy rating in a report on Wednesday, August 16th. Leerink Swann reiterated an outperform rating and issued a $18.00 price target on shares of ObsEva SA in a report on Wednesday, August 16th. Finally, Zacks Investment Research upgraded ObsEva SA from a sell rating to a hold rating in a report on Wednesday, July 19th. Six analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus price target of $18.83.
ObsEva SA (NASDAQ:OBSV) traded down $0.17 during trading on Thursday, hitting $10.79. 11,510 shares of the company’s stock traded hands, compared to its average volume of 22,495.
ObsEva SA (NASDAQ:OBSV) last announced its earnings results on Tuesday, August 15th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.13). During the same period in the prior year, the company posted ($0.30) earnings per share. research analysts predict that ObsEva SA will post -2.37 EPS for the current year.
WARNING: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/obseva-sa-obsv-earns-buy-rating-from-royal-bank-of-canada/1752765.html.
Institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. boosted its holdings in ObsEva SA by 9.7% in the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after acquiring an additional 20,411 shares during the last quarter. Paloma Partners Management Co bought a new position in ObsEva SA in the first quarter valued at about $131,000. Sectoral Asset Management Inc boosted its holdings in ObsEva SA by 181.9% in the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after acquiring an additional 137,331 shares during the last quarter. Finally, VHCP Management II LLC bought a new position in ObsEva SA in the second quarter valued at about $1,283,000. Institutional investors and hedge funds own 48.46% of the company’s stock.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with our FREE daily email newsletter.